Skip to main
CARL

Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed Inc (CARL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Carlsmed Inc. is experiencing robust growth, highlighted by a 98% increase in third-quarter revenue, reaching $13.1 million, driven by a substantial rise in the number of surgeon users, which grew by over 70% year-over-year. The adoption of its AI-enabled personalized spine surgery solutions in a significant $13.4 billion US lumbar fusion market, along with strategic plans to expand into the cervical market by 2026, indicates a strong trajectory for future earnings and overall market penetration. Additionally, the company has achieved a gross margin of 75.9%, exceeding forecasts, as a result of lower contract manufacturing costs and inventory reserve expense reductions, suggesting enhanced operational efficiency.

Bears say

Carlsmed Inc faces a negative outlook largely due to projected revenue shortfalls, with estimates for cervical revenue in FY26 at $2.9 million, which is below prior estimates and reflects challenges in market adoption. The company's potential for success is hindered by several factors, including sluggish uptake of their aprevo technology by new surgeons, anticipated slower growth rates in the overall spine market, and increasing operational expenses. Additionally, competitive pressure from larger players with more diverse portfolios, coupled with adverse reimbursement changes affecting pricing strategies, further compounds the risks associated with Carlsmed's financial stability and market share growth.

Carlsmed Inc (CARL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Carlsmed Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Carlsmed Inc (CARL) Forecast

Analysts have given Carlsmed Inc (CARL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Carlsmed Inc (CARL) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Carlsmed Inc (CARL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.